Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: A new clue to circumvent gastrointestinal toxicity risk

Chemotherapy

Volumn 59, Issue 4, 2014, Pages 260-272

  Inoue, Yutaka ^a   Ikegami, Yoji ^a   Sano, Kazumi ^a   Suzuki, Toshihiro ^a   Yoshida, Hisahiro ^a   Nakamura, Yoichi ^b   Nakagawa, Hiroshi ^c,d   Ishikawa, Toshihisa ^d,e  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHUBU UNIVERSITY   (Japan)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^e RIKEN   (Japan)

Author keywords

ABC transporters; Antitumor activity; Drug drug interaction; Gastrointestinal toxicity; Gefitinib

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FIRTECAN; GEFITINIB; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; DOXORUBICIN; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK REDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL TISSUE; CANCER CHEMOTHERAPY; CANCER INHIBITION; DRUG SELECTIVITY; DRY WEIGHT; GENE EXPRESSION; IC50; SMALL CELL LUNG CANCER;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DIARRHEA; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; QUINAZOLINES; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 84892748210     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000357772     Document Type: Article

References (38)

1. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M: Antitumor activity of 7-ethyl-10[4-(1-piperidino) -1-piperidino] carbonyloxy-camptothecin, a novel watersoluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-5947
2. Sawada S, Okajima S, Aiyama R, Nakata K, Furuta T, Sugino E, Yamaguchi K, Miyasaka T: Synthesis and antitumor activity of 20(S)- camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10- hydroxycamptothecin. Chem Pharma Bull 1991; 39: 1446-1450
3. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-291
4. Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ: Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 2000; 35: 385-402
5. Kaneda N, Nagata H, Yokokura T: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-1720
6. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-4191
7. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme- DNA complex. Biochemistry 1989; 28: 4629-4638
8. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG: Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-1513
9. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ: A model for the mechanism of human topoisomerase I. Science 1998; 279: 1534-1541
10. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP: Mechanism of action of camptothecin. Ann NY Acad Sci 2000; 922: 1-10
11. Horwitz SB, Horwitz MS: Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834-2846
12. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-5082
13. Fassberg J, Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676-684
14. Mi Z, Burke TG: Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994; 33: 10325-10336
15. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, et al: Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports. Ann Oncol 1997; 8: 1049-1051
16. Swami U, Goel S, Mani S: Therapeutic targeting of CPT-11 induced diarrhea: A case of prophylaxis. Curr Drug Targets 2013; 14: 777-779
17. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al: Membrane Transporters in Drug Development: Report from the FDA Critical Path Initiative- Sponsored Workshop. Nat Rev Drug Dis 2010; 9: 215-236
18. Sugiyama Y, Kato Y, Chu X: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42:S44-S49
19. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, et al: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288: 827-832
20. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al: Highaffinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495
21. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, et al: Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005; 49: 337-343
22. Saito H, Hirano H, Nakagawa H, Fukami T, Oosumi K, Murakami K, et al: A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 2006; 317: 1114-1124
23. Ishikawa T, Hirano H, Saito H, Sano K, Ikegami Y, Yamaotsu N, et al: Quantitative structure- activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2. Mini Rev Med Chem 2012; 12: 505-514
24. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, et al: Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65: 1541-1546
25. Wakabayashi-Nakao K, Tamura A, Koshiba S, Toyoda Y, Nakagawa H, Ishikawa T: Production of cells with targeted integration of gene variants of human ABC transporter for stable and regulated expression using the Flp recombinase system. Methods Mol Biol 2010; 648: 139-159
26. Sakurai A, Onishi Y, Hirano H, Seigneuret M, Obanayama K, Kim G, et al: Quantitative SAR analysis and molecular dynamic simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1. Biochemistry 2007; 46: 7678-7693
27. Sano K, Yoshikawa M, Hayasaka S, Satake K, Ikegami Y, Yoshida H, et al: Simple non-ionpaired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 795: 25-34
28. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science 2004; 303: 1800-1805
29. Danceyand J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2: 296-313
30. Ando Y, Hasegawa Y: Clinical pharmacogenetics of irinotecan (CPT-11). A comprehensive review article addressing the genetic polymorphisms of UDP-glucuronosyltransferase gene and irinotecan-induced adverse reactions. Drug Metab Rev 2005; 37: 565-574
31. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan- induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-5159
32. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al: UGT1A1 . 28 polymorphism as a determinant of irinotecan disposition and adverse reactions. Pharmacogenomics J 2002; 2: 43-47
33. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388
34. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-682
35. Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K, et al: Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15: 35-41
36. Nakamura Y, Satake K, Sano K, Ito A, Yoshikawa M, Ikegami Y, et al: Gefitinib increases serum concentration of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats. Chemotherapy 2008; 54: 485-491
37. Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, et al: Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009; 27: 4599-4604
38. Crabb SJ, Bradbury J, Nolan L, Selman D, Muthuramalingam SR, Cave J, et al: A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. Chemotherapy 2012; 58: 257-263